Literature DB >> 33447831

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques.

Neeltje van Doremalen1, Jyothi N Purushotham1,2, Jonathan E Schulz1, Myndi G Holbrook1, Trenton Bushmaker1, Aaron Carmody3, Julia R Port1, Claude K Yinda1, Atsushi Okumura1, Greg Saturday4, Fatima Amanat5,6, Florian Krammer5, Patrick W Hanley4, Brian J Smith4, Jamie Lovaglio4, Sarah L Anzick3, Kent Barbian3, Craig Martens3, Sarah Gilbert2, Teresa Lambe2, Vincent J Munster1.   

Abstract

Intramuscular vaccination with ChAdOx1 nCoV-19/AZD1222 protected rhesus macaques against pneumonia but did not reduce shedding of SARS-CoV-2. Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein. Viral load in swabs obtained from intranasally vaccinated hamsters was significantly decreased compared to controls and no viral RNA or infectious virus was found in lung tissue, both in a direct challenge and a transmission model. Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue. In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines.

Entities:  

Year:  2021        PMID: 33447831      PMCID: PMC7808328          DOI: 10.1101/2021.01.09.426058

Source DB:  PubMed          Journal:  bioRxiv


  44 in total

1.  A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data.

Authors:  Heng Li
Journal:  Bioinformatics       Date:  2011-09-08       Impact factor: 6.937

2.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

3.  A serological assay to detect SARS-CoV-2 seroconversion in humans.

Authors:  Fatima Amanat; Daniel Stadlbauer; Shirin Strohmeier; Thi H O Nguyen; Veronika Chromikova; Meagan McMahon; Kaijun Jiang; Guha Asthagiri Arunkumar; Denise Jurczyszak; Jose Polanco; Maria Bermudez-Gonzalez; Giulio Kleiner; Teresa Aydillo; Lisa Miorin; Daniel S Fierer; Luz Amarilis Lugo; Erna Milunka Kojic; Jonathan Stoever; Sean T H Liu; Charlotte Cunningham-Rundles; Philip L Felgner; Thomas Moran; Adolfo García-Sastre; Daniel Caplivski; Allen C Cheng; Katherine Kedzierska; Olli Vapalahti; Jussi M Hepojoki; Viviana Simon; Florian Krammer
Journal:  Nat Med       Date:  2020-05-12       Impact factor: 53.440

4.  A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.

Authors:  Matthew D J Dicks; Alexandra J Spencer; Nick J Edwards; Göran Wadell; Kalifa Bojang; Sarah C Gilbert; Adrian V S Hill; Matthew G Cottingham
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

5.  Pathogenesis and transmission of SARS-CoV-2 in golden hamsters.

Authors:  Sin Fun Sia; Li-Meng Yan; Alex W H Chin; Kevin Fung; Ka-Tim Choy; Alvina Y L Wong; Prathanporn Kaewpreedee; Ranawaka A P M Perera; Leo L M Poon; John M Nicholls; Malik Peiris; Hui-Ling Yen
Journal:  Nature       Date:  2020-05-14       Impact factor: 49.962

6.  Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection.

Authors:  Michael W Russell; Zina Moldoveanu; Pearay L Ogra; Jiri Mestecky
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

7.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

8.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

9.  Foodborne transmission of nipah virus in Syrian hamsters.

Authors:  Emmie de Wit; Joseph Prescott; Darryl Falzarano; Trenton Bushmaker; Dana Scott; Heinz Feldmann; Vincent J Munster
Journal:  PLoS Pathog       Date:  2014-03-13       Impact factor: 6.823

10.  Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.

Authors:  Vincent J Munster; Friederike Feldmann; Brandi N Williamson; Neeltje van Doremalen; Lizzette Pérez-Pérez; Jonathan Schulz; Kimberly Meade-White; Atsushi Okumura; Julie Callison; Beniah Brumbaugh; Victoria A Avanzato; Rebecca Rosenke; Patrick W Hanley; Greg Saturday; Dana Scott; Elizabeth R Fischer; Emmie de Wit
Journal:  Nature       Date:  2020-05-12       Impact factor: 49.962

View more
  11 in total

1.  Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.

Authors:  Pedro M Folegatti; Daniel Jenkin; Susan Morris; Sarah Gilbert; Denny Kim; James S Robertson; Emily R Smith; Emalee Martin; Marc Gurwith; Robert T Chen
Journal:  Vaccine       Date:  2022-06-14       Impact factor: 4.169

Review 2.  Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines.

Authors:  Violette Mouro; Alain Fischer
Journal:  Mucosal Immunol       Date:  2022-05-03       Impact factor: 8.701

Review 3.  Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?

Authors:  Mattia Tiboni; Luca Casettari; Lisbeth Illum
Journal:  Int J Pharm       Date:  2021-05-06       Impact factor: 6.510

Review 4.  SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity.

Authors:  Francesco Blasi; Andrea Gramegna; Giovanni Sotgiu; Laura Saderi; Antonio Voza; Stefano Aliberti; Francesco Amati
Journal:  Respir Med       Date:  2021-03-06       Impact factor: 4.582

Review 5.  COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.

Authors:  Kuldeep Dhama; Manish Dhawan; Ruchi Tiwari; Talha Bin Emran; Saikat Mitra; Ali A Rabaan; Saad Alhumaid; Zainab Al Alawi; Abbas Al Mutair
Journal:  Hum Vaccin Immunother       Date:  2022-03-08       Impact factor: 4.526

6.  SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.

Authors:  David W Hawman; Kimberly Meade-White; Jacob Archer; Shanna S Leventhal; Drew Wilson; Carl Shaia; Samantha Randall; Amit P Khandhar; Kyle Krieger; Tien-Ying Hsiang; Michael Gale; Peter Berglund; Deborah Heydenburg Fuller; Heinz Feldmann; Jesse H Erasmus
Journal:  Elife       Date:  2022-02-22       Impact factor: 8.713

7.  Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern.

Authors:  Dominik A Rothen; Pascal S Krenger; Aleksandra Nonic; Ina Balke; Anne-Cathrine S Vogt; Xinyue Chang; Alessandro Manenti; Fabio Vedovi; Gunta Resevica; Senta M Walton; Andris Zeltins; Emanuele Montomoli; Monique Vogel; Martin F Bachmann; Mona O Mohsen
Journal:  Allergy       Date:  2022-04-15       Impact factor: 14.710

8.  ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.

Authors:  Neeltje van Doremalen; Jonathan E Schulz; Danielle R Adney; Taylor A Saturday; Robert J Fischer; Claude Kwe Yinda; Nazia Thakur; Joseph Newman; Marta Ulaszewska; Sandra Belij-Rammerstorfer; Greg Saturday; Alexandra J Spencer; Dalan Bailey; Colin A Russell; Sarah C Gilbert; Teresa Lambe; Vincent J Munster
Journal:  Nat Commun       Date:  2022-08-08       Impact factor: 17.694

9.  Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice.

Authors:  Xingxing Li; Ling Wang; Jingjing Liu; Enyue Fang; Xiaohui Liu; Qinhua Peng; Zelun Zhang; Miao Li; Xinyu Liu; Xiaohong Wu; Danhua Zhao; Lihong Yang; Jia Li; Shouchun Cao; Yanqiu Huang; Leitai Shi; Hongshan Xu; Yunpeng Wang; Yue Suo; Guangzhi Yue; Jianhui Nie; Weijin Huang; Wenjuan Li; Yuhua Li
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

10.  SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta.

Authors:  Neeltje van Doremalen; Manmeet Singh; Taylor A Saturday; Claude Kwe Yinda; Lizzette Perez-Perez; W Forrest Bohler; Zachary A Weishampel; Matthew Lewis; Jonathan E Schulz; Brandi N Williamson; Kimberly Meade-White; Shane Gallogly; Atsushi Okumura; Friederike Feldmann; Jamie Lovaglio; Patrick W Hanley; Carl Shaia; Heinz Feldmann; Emmie de Wit; Vincent J Munster; Kyle Rosenke
Journal:  bioRxiv       Date:  2022-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.